Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica

Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7,  Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either BTK inhibitor-naïve or treatment-naïve. Jaypirca is a non-covalent Bruton tyrosine kinase inhibitor, while Imbruvica is a covalent BTK inhibitor.

The results showed that Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib in the intent-to-treat (ITT) population, and also had numerically higher ORR rates.

In addition, progression-free survival (PFS), while immature, and trended in pirtobrutinib’s favor in comparison with ibrutinib across all populations. This included a 76% drop in the risk of disease progression or death in treatment-naïve patients, which is the subgroup that has the longest follow-up.

Management stated that BRUIN CLL-314 marks the first randomized study comparing covalent and non-covalent BTK inhibitors and directly comparing any BTK inhibitors in the treatment-naïve setting, providing significant findings for advancements in the field and patient care. The efficacy results, along with the safety profile of pirtobrutinib, offer solid evidence supporting pirtobrutinib’s role in the treatment course for patients with CLL or SLL.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.